Sentence examples for greater mean decrease from inspiring English sources

Horses with more compliant owners had a greater mean decrease in BW and BCS (P <.01) than those of noncompliant owners.

Likewise, horses with no pasture access had a greater mean decrease in BW and BCS (P <.01) than continuously grazing horses.

No interaction between treatment and sex was seen but male patients had a greater mean decrease in prolactin at week 26 compared with the female patients (22.67 mg/dL SE 2.15 vs 8.95 mg/dL SE 2.61, respectively).

Generally, switching during the second year from monthly to PRN treatment resulted in a greater mean decrease in vision, but still the mean gain in VA was similar for both drugs (bevacizumab-ranibizumab difference, −1.4 letters).

All three groups showed a statistically significant mean decrease in patients' AP activity with a greater mean decrease in the CPB and DSC groups than in the non-bypass group.

Generally, switching from monthly to as-needed treatment resulted in a greater mean decrease in vision during year 2 (−2.2 letters; p=0.03) and a lower proportion without fluid (−19%; p<0.0001).

The younger cohort, age 5 and under, showed significantly greater mean decreases in two markers of immune dysregulation, CD3% and CD4%, than the older cohort.

Further, we found patients without T2D had greater mean decreases in BMI than patients with T2D (0.81 kg/m2 vs. 0.74 kg/m, P < 0.0001).

For both rituximab + MTX dose groups there were significantly greater mean decreases in all individual components of the ACR core set (p≤0.0007), and significantly greater mean changes in DAS28-ESR (p<0.0001) versus the placebo + MTX group.

Improvements in physical function were also sustained throughout the second year of treatment with both rituximab+MTX doses resulting in significantly greater mean decreases in HAQ-DI score compared with placebo+MTX (p<0.0001 at week 104) (figure 4).

At week 24, rituximab-treated STN patients demonstrated a greater mean (±SD) decrease from baseline in DAS28-ESR (−2.37±1.51) than STY patients (−2.10±1.46); this was consistent with values observed in the placebo-treated STY and STN groups (figure 1A).